Sign In  |  Register  |  About Walnut Creek Guide  |  Contact Us

Walnut Creek, CA
September 01, 2020 1:43pm
7-Day Forecast | Traffic

  • Search Hotels in Walnut Creek Guide

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abcellera Biologics Inc (NQ: ABCL )

2.720 +0.050 (+1.87%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,428,359
Open 2.660
Bid (Size) 2.650 (14)
Ask (Size) 2.770 (5)
Prev. Close 2.670
Today's Range 2.610 - 2.770
52wk Range 2.335 - 6.055
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AbCellera to Present at Upcoming Investor Conferences in December and January
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024
From AbCellera Biologics Inc.
Via Business Wire

Performance

YTD
-52.53%
-52.53%
1 Month
-4.23%
-4.23%
3 Month
+8.37%
+8.37%
6 Month
-29.35%
-29.35%
1 Year
-38.60%
-38.60%

More News

Read More
AbCellera Biologics (ABCL) Q3 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
AbCellera Reports Q3 2024 Business Results
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Present at Upcoming Investor Conferences in November 2024
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024
From AbCellera Biologics Inc.
Via Business Wire
AI-Focused Drug Discovery Stocks +6% Last Week Vs. -8% Previous Week
Via Talk Markets
AI-Focused Drug Discovery Stocks Portfolio -8% W/e Sept 6th
Via Talk Markets
Our AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone!
Via Talk Markets
Topics Economy
Exposures Economy
AbCellera to Present at Upcoming Investor Conferences in September
From AbCellera Biologics Inc.
Via Business Wire
Our AI-Focused Drug Discovery Stocks Portfolio Was Up Almost 7% Last Week
Via Talk Markets
This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Via Benzinga
AI-Focused Drug Discovery Stocks Portfolio Hit Hard: Down 14% MTD
Via Talk Markets
AbCellera Biologics (ABCL) Q2 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
AbCellera Reports Q2 2024 Business Results
From AbCellera Biologics Inc.
Via Business Wire
AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines
From AbCellera Biologics Inc.
Via Business Wire
AI-Focused Drug Discovery Stocks Portfolio Up 7% Last Week; Up 19% MTD
Via Talk Markets
"Bubble" In AI/Semiconductor Stocks Began To Re-Inflate On Friday
Via Talk Markets
Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?
Via The Motley Fool
AI-Powered Drug Discovery Stocks Portfolio Up 14% MTD; Still Down 30% YTD
Via Talk Markets
Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD
Via Talk Markets
3 Biotech Stocks That Can Gain Exponentially By Leveraging AI
Via Talk Markets
AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024
From AbCellera Biologics Inc.
Via Business Wire
Largest Clinical-Stage BioTech Drug Stocks Declined 6%
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 WalnutCreekGuide.com & California Media Partners, LLC. All rights reserved.